Skip to main content
. 2023 Apr 27;15(5):1346. doi: 10.3390/pharmaceutics15051346

Figure 1.

Figure 1

Augmented cancer–immunity cycle. The classic activation, through MHCI-CD8-acivated T cells, is on the upper side. The MHCII-CD4-NK axis is at the bottom. Ag—antigen, Ab—antibody, TCR—T cell receptor, and FcγIIIa—low affinity immunoglobulin gamma Fc region receptor III-A (CD16a).